Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) mean price target has been set at $140.83 by Thomson Reuters. The group worked out on the stock recommendations given by analysts in the First Call poll. Further, it is possible that the company may register per share earnings of $1.26 in the near-term quarter and $3.45 for the ongoing fiscal. The market cap of Ligand Pharmaceuticals Incorpor was recorded at $2.23B after the stock closed at $106.48 in last trading day.
What The Valuation Says?
The price/earnings ratio is taken in the list of ratios that leads to a stock’s valuation. Commonly named as P/E ratio, it helps investors know where the company stands in the market. It is derived by dividing share’s latest price by per-share earnings. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has a P/E ratio of 10.07. Investors can identify how the stock is doing in the market by estimating Price-to-Earnings Growth ratio.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PEG ratio sits at 0.68. A low PEG ratio offers an investment opportunity to the opportunistic traders and investors. In case a stock has a reading in between 0 and 1, it represents undervalued stock. A reading of 1 and 2 represents fairly priced stocks.
The technical analysis of Ligand Pharmaceuticals Incorpor visibly illustrates that the 50-day MA of Ligand Pharmaceuticals Incorpor is $124.21, and stock is trading $-17.39 points away or -14.00% from its 50-day moving average of $124.21. Further it is trading $-7.26 or -6.37% away its 200-day moving average of $114.08. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) 52-week high is $139.79 and the 52-week low is $79.66. This represents that if the stock moves $-32.97 points up on the chart to it will make a 52-week high. But, if it declines +34.09%, then the shares price can hit a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...